CG Oncology, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 48.61 million compared to USD 35.44 million a year ago. Basic loss per share from continuing operations was USD 15.65 compared to USD 11.71 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28.5 USD | -5.06% | -21.42% | 0.00% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 1.9B | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- CGON Stock
- News CG Oncology, Inc.
- CG Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023